Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps

Kimia Sorouri; Filipa Lynce; Colleen M. Feltmate; Michelle R. Davis; Michael G. Muto; Panagiotis A. Konstantinopoulos; Elizabeth H. Stover; Allison W. Kurian; Sarah J. Hill; Ann H. Partridge; Sara M. Tolaney; Judy E. Garber; Brittany L. Bychkovsky

Journal ArticleOPEN ACCESS

Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps

Sorouri K
Lynce F
Feltmate C
et al.

JCO Precision Oncology (2023) (7)

DOI: 10.1200/po.23.00290

9Citations

13Readers

Abstract

BRCA1/2 carriers face ↑ EC risk; ↑ research needed to inform rr-hysterectomy in this population.

Cite

CITATION STYLE

APA

Sorouri, K., Lynce, F., Feltmate, C. M., Davis, M. R., Muto, M. G., Konstantinopoulos, P. A., … Bychkovsky, B. L. (2023). Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. JCO Precision Oncology, (7). https://doi.org/10.1200/po.23.00290

Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps

Abstract

Cite

Register to see more suggestions